Why Entera Bio's Stock Is Surging Higher Today

Loading...
Loading...

Entera Bio Ltd ENTX shares are trading higher on heavy volume Friday after the company announced the Phase 2 clinical trial of EB613 met its primary endpoint.

According to Entera, EB613 is an orally delivered human parathyroid hormone (1-34), or PTH, drug candidate positioned as the first potential once daily, oral, bone building (anabolic) treatment for osteoporosis patients.

Entera Bio is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with a significant unmet medical need.

Trading has been halted three times as of 10:10 a.m. ET. Entera Bio shares are trading higher by 103.47% at $8.22 at the time of publication.

Posted In: NewsMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...